You SC, Rho Y, Bikdeli B, et al. - Researchers performed a retrospective cohort analysis to examine the link of ticagrelor vs clopidogrel with ischemic and hemorrhagic events among patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) in clinical practice. For this purpose, 2 United States electronic health record–based databases and 1 nationwide South Korean database were utilized. A large-scale propensity score algorithm was employed to match patients. Findings demonstrated that ticagrelor, vs clopidogrel, was not related to a significant difference in the risk of net adverse clinical events at 12 months in patients with ACS who received PCI in routine clinical practice. As the likelihood of unmeasured confounders cannot be excluded, further inquiry is required to ascertain if ticagrelor is more effective than clopidogrel in this setting.